Shop by category
Growth Hormone Axis ResearchRegeneration ResearchPeptide BioregulatorsCognitive & Neuropeptide ResearchMetabolic & Cellular ResearchMelanocortin & Endocrine ResearchDermal Peptide ResearchImmune & Thymic ResearchGHK-Cu research spans more than fifty years. It reaches across copper chemistry, connective tissue biology, and more recently the nervous system. The compound is a copper tripeptide, and most of what is known about it comes from cell culture and animal models. Human data exist, but they are limited. The two controlled trials that isolated it did not meet their objective endpoints. This article summarizes what the published literature has investigated. It describes research findings, not outcomes anyone should expect.
GHK is the tripeptide glycyl-L-histidyl-L-lysine. Its molecular formula is C14H24N6O4 and its molecular weight is 340.38 g/mol. PubChem lists the free peptide as CID 73587, under CAS 49557-75-7.
The peptide binds copper(II) with high affinity. Spectroscopic work in solution showed that copper is coordinated by nitrogen atoms, one of which sits in the histidine imidazole ring.[1] That same study found the structure seen by X-ray crystallography in the solid state does not persist in solution.
The resulting complex is written as GHK-Cu. PubChem records it as prezatide copper under CAS 89030-95-5, formula C14H23CuN6O4+, molecular weight 402.92 g/mol. That is 62.54 more than the free peptide, not the 63.5 of a bare copper atom, because the ligand gives up a proton when it coordinates. Research-grade GHK-Cu is supplied as this copper-bound form.
Pickart and Thaler first reported the tripeptide in 1973. They isolated it from human serum and found that it prolonged the survival of cultured normal liver cells.[2] Later review work reports that plasma levels fall with age.[3]
That age decline is worth reading carefully. The figures usually quoted for it appear in a review that gives no supporting primary citation. They are best treated as a review-level assertion rather than a settled measurement.
Two mechanisms are proposed for this copper peptide, and they point in different directions.
The first is copper delivery. The complex carries copper into the cellular environment, where copper acts as a cofactor for enzymes involved in assembling the extracellular matrix.
The second is copper buffering. Metal-free GHK binds loose copper and lowers its redox activity, which is a scavenging role rather than a delivery one.
Which mechanism is relevant depends on whether the peptide arrives already loaded with copper. That distinction runs through the entire literature, and papers frequently blur it.
Two points from the binding chemistry complicate the delivery account. Solution studies found that GHK and copper form several species rather than one clean complex, and that GHK competes with albumin for copper rather than dominating it.[4] Calorimetry later showed that albumin's own copper-binding motif holds copper(II) somewhat more tightly than GHK does.[5] Neither finding rules out a delivery role, but both mean the peptide is not the obvious destination for copper in a protein-rich environment.
The most internally consistent body of GHK-Cu research concerns the extracellular matrix. This is the scaffold of collagen, elastin and glycosaminoglycans that gives connective tissue its structure.
Maquart and colleagues reported that the copper tripeptide stimulated collagen synthesis in cultured fibroblasts.[6] The effect was independent of any change in cell number. That detail matters, because it rules out the rise being a by-product of simply having more cells.
Wegrowski and colleagues extended the question to the wider matrix. GHK-Cu stimulated the synthesis of sulfated glycosaminoglycans, specifically dermatan sulfate and heparan sulfate.[7] Hyaluronic acid, which is not sulfated, was unaffected. The word sulfated is load-bearing here, and a broader claim would misstate the finding.
The concentration response was biphasic rather than steady. Synthesis rose to a peak and then fell back toward control levels as concentrations increased further.
Matrix turnover was also affected, not just deposition. Siméon and colleagues reported that GHK-Cu stimulated expression of matrix metalloproteinase-2 in fibroblast cultures.[8] This is the basis for describing the peptide as modulating the balance between matrix breakdown and matrix assembly. The fibroblasts in that study were rat, not human.
These are cell-culture results. They describe what cultured cells did, not a predicted result in a living organism.
GHK-Cu wound healing research then moved into animals. In a rat wound-chamber model, the complex increased dry weight, DNA, total protein, collagen and glycosaminoglycan content.[9] Messenger RNA for type I and type III collagen rose, while TGF-beta messenger RNA did not. An unrelated control tripeptide produced no significant effect, which argues for a degree of specificity.
A second rat study examined the same wound setting and reported modulation rather than uniform increase.[10] Decorin messenger RNA rose while biglycan messenger RNA fell. Research-grade GHK-Cu from Purepeptides corresponds to the copper-bound complex used throughout this line of work.
Both studies injected the complex directly into an implanted chamber in rats. Neither used topical application, and neither involved humans. These animal wound findings should be read alongside the controlled human ulcer trial described below, which did not reproduce them.
Anyone comparing studies needs to know which entity was actually tested. The literature splits on this point, and the split is not a technicality.
The connective tissue work described above used the copper complex throughout. So did both controlled human trials.
Much of the newer nervous-system work used metal-free GHK instead. Min and colleagues showed in vitro that GHK bound copper, reduced its redox activity, and protected cultured mouse central nervous system cells from copper- and zinc-induced death.[11] Two rat intracerebral hemorrhage studies dissolved plain GHK in saline.[12][13] A study in aging mice used copper-free peptide deliberately, and the authors explained why.[14]
One rodent nervous-system study is the exception. Mice in a transgenic Alzheimer's model received the copper-loaded complex, even though that paper's title describes the treatment as GHK peptide.[15] Its only comparator was saline. There was no metal-free arm and no copper-only arm, so it cannot separate the peptide's contribution from copper's.
The peptide appears repeatedly in Connectivity Map screens. Campbell and colleagues derived a gene signature from emphysematous human lung tissue and found GHK predicted to reverse it. They then tested it in cultured human lung fibroblasts.[16] Zhou and colleagues later surfaced GHK independently through network modeling in Alzheimer's disease, with validation in a neuroblastoma cell line.[17] Both used the metal-free peptide, so neither is evidence about the copper complex.
The widely repeated claim that GHK resets thousands of genes has a narrower origin than its circulation suggests. It comes from a secondary re-analysis of three Connectivity Map profiles drawn from prostate and breast cancer cell lines.[18] No new experiments were performed. The threshold was a raw fold change, reported without significance testing or correction for multiple comparisons. The authors are affiliated with a company that sells copper peptide products.
Independence is a real issue in this field. The connective tissue core comes substantially from one French research group, and the compound's original discoverer, a commercially interested party, appears across the early work. The binding chemistry and the Connectivity Map signal are the parts that unrelated groups have reproduced.
Human evidence is the weakest part of GHK-Cu research, and it should not be read as confirming the preclinical picture.
Two controlled trials isolated a copper tripeptide preparation as the variable. Both were negative on their objective endpoints.
Bishop and colleagues ran the larger of the two. In 86 evaluable patients with venous stasis ulcers, a copper tripeptide cream performed no better than an inert vehicle.[19] Silver sulfadiazine outperformed both.
Miller and colleagues studied skin after CO2 laser resurfacing, with 13 patients completing. Blinded evaluation and computerized analysis found no significant difference in erythema, wrinkles, or overall skin quality.[20] Patient self-report favored the GHK-Cu regimen, but that endpoint was unblinded and is the one most exposed to expectancy.
Other human reports exist. They are case reports, single-arm studies, or trials of multi-ingredient formulations. In those designs GHK-Cu cannot be separated from the other active ingredients, or from the devices used to apply them.
Delivery is the largest unresolved problem. Li and colleagues found that almost no peptide and almost no copper crossed intact human skin.[21] Meaningful permeation required microneedle pretreatment. Roughly five times more copper than peptide crossed even then.
An earlier permeation study measured copper by mass spectrometry rather than tracking the intact peptide.[22] It therefore cannot demonstrate that the complex arrived assembled.
Stability is a second constraint. GHK-Cu is highly hydrophilic and degrades under basic and oxidative conditions.[23] A review of anti-wrinkle peptides concluded that adequate skin permeability is routinely assumed rather than demonstrated.[24]
Copper itself is double-edged. It is essential in trace amounts and harmful in excess. Whether GHK-Cu is better understood as delivering copper or as sequestering it likely depends on tissue and context, and that question is unresolved.
GHK-Cu is an endogenous copper tripeptide with a reasonably consistent preclinical record in connective tissue. Cell-culture and rodent studies report effects on collagen, on matrix components, and on matrix turnover. Those findings have not so far translated into positive controlled human trials.
The most useful distinction for reading this literature is which entity a given study used. Copper-loaded GHK-Cu and metal-free GHK are different test articles, and paper titles do not always make the difference clear.
Two controlled human trials exist, and both were negative on their objective endpoints. A copper tripeptide cream performed no better than an inert vehicle for venous stasis ulcers in 86 evaluable patients, with silver sulfadiazine outperforming both. A separate trial found no significant blinded difference in erythema, wrinkles, or overall skin quality after CO2 laser resurfacing.
No. GHK is the metal-free tripeptide, C14H24N6O4 at 340.38 g/mol. GHK-Cu is the copper(II) complex, C14H23CuN6O4+ at 402.92 g/mol. The literature studies them separately: the connective tissue work and both human trials used the copper-bound form, while much of the newer nervous-system research used metal-free GHK.
No. A search of the FDA's approved-product records returns no drug product containing GHK-Cu as an active ingredient. It does appear in cosmetic and over-the-counter topical products, but in those it is not an active ingredient and their status rests on other constituents.
Partially. Much of the core connective tissue evidence comes from one French research group. The separate gene-expression signal has been reproduced independently, by Campbell and colleagues in emphysema and by Zhou and colleagues in Alzheimer's disease modeling, though both used the metal-free peptide. The better-known claim that GHK resets thousands of genes has not been independently reproduced; it traces to a secondary re-analysis of cancer cell line profiles by commercially affiliated authors.
References
The 1973 paper that introduced GHK had nothing to do with skin, or with copper. How a tripeptide from blood took fifteen years to become a matrix molecule.
A convincing blue color is easy to fake. Here's the plain-English version of the two checks that actually prove GHK-Cu's copper is real.
A PubMed search for acetyl octapeptide-3 returns two papers, and neither tests it alone. ClinicalTrials.gov lists none. What the SNAP-8 record contains.
Pal-GHK is copper-free palmitoyl tripeptide-1, not GHK-Cu. ClinicalTrials.gov lists no trial of it, and every human result for it alone is from one maker.
Matrixyl is a Sederma trademark for palmitoyl pentapeptide-4. A review of the mostly manufacturer-funded topical research on Pal-KTTKS, and its gaps.
